Navigation Links
MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
Date:2/5/2013

PHILADELPHIA Researchers have identified two molecules that could potentially serve as biomarkers in predicting brain metastases in patients with breast cancer, according to data published in Cancer Research, a publication of the American Association for Cancer Research.

Currently, most deaths from breast cancer are a result of metastatic disease. New research shows that cancer stem-like cells commonly defined as cells within a tumor with the capacity to initiate a new tumor, proliferate rapidly, differentiate and cause chemotherapy resistance may play a role in breast cancer metastasis.

"Recent research has shown that microRNAs are involved in tumor initiation and progression, and we hypothesized that they also may play a role in metastasis, particularly in relation to cancer stem-like cells," said Kounosuke Watabe, Ph.D., associate director for basic science at the University of Mississippi Medical Center in Jackson, Miss.

Watabe and colleagues performed microRNA profile analysis on RNA extracted from cancer stem-like cells isolated from a human breast cancer cell line and two highly metastatic variants of this cell line.

"We found that miR-7 is a metastasis suppressor in cancer stem-like cells," Watabe said. "When we increased expression of miR-7 in cancer stem-like cells from metastatic human breast cancer cell lines, it suppressed their metastatic properties."

Next, the researchers examined the molecular pathway downstream of miR-7 to find its targets and discovered that miR-7 suppressed expression of KLF4.

"High expression of KLF4 was inversely associated with brain metastasis-free survival but was not associated with bone metastasis," Watabe said. "This was confirmed in an animal model when we found that expression of miR-7 significantly suppressed the ability of cancer stem-like cells to metastasize to the brain but not the bone."

Finally, the researchers tested tumor samples from patients with breast cancer whose disease metastasized to the brain. Results showed that miR-7 was downregulated and KLF4 was upregulated. The miR-7/KLF4 axis played a critical role in cancer stem-like cell brain metastasis, according to Watabe.

Few treatments currently exist for brain metastasis because few drugs can penetrate the bloodbrain barrier, which prevents chemotherapy from reaching the brain.

"Cancer cells find the brain to be a kind of sanctuary where they can survive longer," Watabe said. "It is possible that miR-7 and KLF4 may serve as diagnostic or prognostic markers, or therapeutic targets for the prediction of, or treatment of, brain metastasis."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. A microRNA prognostic marker identified in acute leukemia
2. Pint-size microRNAs show promise against weighty problem, researchers say
3. MicroRNAs can convert normal cells into cancer promoters
4. Hepatitis B virus promotes oncogenesis through microRNA modulation
5. Molecule movements that make us think
6. Prions in the brain eliminated by homing molecules
7. Researchers identify a life-and-death molecule on chronic leukemia cells
8. Inhibitors of shuttle molecule show promise in acute leukemia
9. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
10. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
11. Molecule found that inhibits recovery from stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... It can ... holiday presents for their four-legged family members as they do for their human friends ... pet parents’ desire to find the highest quality and most innovative pet products has ...
(Date:12/6/2016)... GA (PRWEB) , ... December 06, 2016 , ... ... and the impact of new federal healthcare regulations at the 7th annual Health ... Centre, Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare & ...
(Date:12/6/2016)... ... 2016 , ... The V Foundation for Cancer Research, a ... to Lose fundraising campaign. As the V Foundation’s boldest initiative to date, Not ... The campaign aims to raise $200 million by 2020 and strategically fund emerging, ...
(Date:12/6/2016)... ... 2016 , ... Just in time for the holiday season, the celebrated paleo ... for Honeyville’s new Organic Quinoa Flour product for sale at Costco stores throughout the ... , “I think it’s wonderful that a growing number of retailers such as ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This ... label design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
(Date:12/5/2016)... , Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., ... presented data from two Phase I trials evaluating ... the 58th annual meeting of the American Society ... California . The two datasets show encouraging ... myeloid leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell ...
(Date:12/5/2016)... YORK, Pa. , Dec. 5, 2016  Pennsylvania ... of Drug and Alcohol Programs Gary Tennis ... reversal drug, at Minnich,s Pharmacy in York ... standing order signed by Dr. Levine as a prescription ... "It,s important to remember that any ...
Breaking Medicine Technology: